Common Contracts
5 similar Loan and Security Agreement contracts by Axovant Sciences Ltd., BICYCLE THERAPEUTICS PLC, Dermavant Sciences LTD, others
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 1st, 2020 • BICYCLE THERAPEUTICS PLC • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2020 and is entered into by and among BICYCLE THERAPEUTICS PLC, a public limited company organized under the laws of England and Wales (“Parent”), BICYCLETX LIMITED, a private company limited by shares organized under the laws of England and Wales (“BicycleTx”), BICYCLERD LIMITED, a private company limited by shares organized under the laws of England and Wales (“BicycleRD”), BICYCLE THERAPEUTICS INC., a Delaware corporation (“Bicycle US”) and each of Parent’s Subsidiaries that delivers a Joinder Agreement pursuant to Section 7.13 of the Agreement (hereinafter collectively referred to as “Borrowers” and each, “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as the “Lenders”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in suc
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 14th, 2019 • Urovant Sciences Ltd. • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of February 20, 2019 and is entered into by and between Urovant Sciences Ltd., an exempted company limited by shares and organized under the laws of Bermuda (“Parent”), Urovant Holdings Limited, a private limited company incorporated under the laws of England and Wales (“Urovant England”), Urovant Sciences GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and organized under the laws of Switzerland (“Urovant Switzerland”, and each of Parent’s Subsidiaries that delivers a Joinder Agreement pursuant to Section 7.13 of the Agreement (hereinafter collectively referred to as the “Borrowers” and each, a “Borrower”), Urovant Sciences, Inc., a Delaware corporation (“Urovant USA” or the “Guarantor”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as “Lender”) and HERCULES CAPITAL, INC., formerly known as Hercules Techno
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 10th, 2019 • Dermavant Sciences LTD • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of May 24, 2019 and is entered into by and between DERMAVANT SCIENCES LTD., an exempted company organized under the laws of Bermuda (“Parent”), DERMAVANT HOLDINGS LIMITED, a private limited company incorporated under the laws of England and Wales (“Dermavant England”), DERMAVANT SCIENCES GMBH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and organized under the laws of Switzerland (“Dermavant Switzerland”), and each of Parent’s Subsidiaries that delivers a Joinder Agreement pursuant to Section 7.13 of the Agreement (hereinafter collectively referred to as the “Borrowers” and each, a “Borrower”), DERMAVANT SCIENCES, INC., a Delaware corporation (“Dermavant Delaware”, and together with each other guarantor party hereto from time to time, each a “Guarantor”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as “Lende
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • February 13th, 2018 • Myovant Sciences Ltd. • Pharmaceutical preparations • New York
THIS LOAN AND SECURITY AGREEMENT is made and dated as of October 16, 2017 and is entered into by and between Myovant Sciences Ltd., an exempted company incorporated and organized under the laws of Bermuda (“Parent” or “Borrower”), Myovant Holdings Limited, a company incorporated in England and Wales with registered number 10317663 whose registered address is Suite 1, 3rd Floor 11-12 St. James’s Square, London, United Kingdom, SW1Y 4LB (“Myovant England”), Myovant Sciences GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and organized under the laws of Switzerland (“Myovant Switzerland”), Myovant Sciences Ireland Limited, a private company limited by shares organized under the laws of Ireland with registered number 601541 whose registered address is 24/26 City Quay, Dublin 2 (“Myovant Ireland”), Myovant Sciences, Inc., a Delaware corporation (“Myovant Delaware” and, together with Myovant England and Myovant Switzerland and Myovant Ireland, each a “G
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 13th, 2017 • Axovant Sciences Ltd. • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of February 2, 2017 and is entered into by and between Axovant Sciences Ltd., an exempted company organized under the laws of Bermuda (“Parent”), Axovant Holdings Limited, a private limited company organized under the laws of England and Wales (“Axovant England”), Axovant Sciences GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and organized under the laws of Switzerland (“Axovant Switzerland”), and each of Parent’s Subsidiaries that delivers a Joinder Agreement pursuant to Section 7.13 of the Agreement (hereinafter collectively referred to as the “Borrowers” and each, a “Borrower”), Axovant Sciences, Inc., a Delaware corporation (the “Guarantor”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as “Lender”) and HERCULES CAPITAL, INC., formerly known as Hercules Technology Growth Capital, Inc., a Maryland corp
